Shouldn't this term be moved inside MI:0230 (membrane bound complementation assay) ?
Please, also note, that some of the cytoplasmic complementation assays (ie these listed within
MI:0228) can be adopted to membrane proteins which makes the annotation rather confusing.
On top of this cellular localization (membrane/cytoplasm; also nuclear ? some of the complementation
assays, most notably Y2H, are nucleus-bound) is, conceptually, orthogonal to interaction detection
and thus should be kept away from the iteraction detection terms. As far as I'm concerned, the optimal
arrangement would be to get rid of MI:0230 with MI:0228 altogether, place all the child terms, together
with MI:0232 (transcriptional complementation assay) branch directly within MI:0090 (protein
complementation assay), and, finally, merge MI:0229 and MI:0809 into one generic term.
Shouldn't this term be moved inside MI:0230 (membrane bound complementation assay) ? Please, also note, that some of the cytoplasmic complementation assays (ie these listed within MI:0228) can be adopted to membrane proteins which makes the annotation rather confusing. On top of this cellular localization (membrane/cytoplasm; also nuclear ? some of the complementation assays, most notably Y2H, are nucleus-bound) is, conceptually, orthogonal to interaction detection and thus should be kept away from the iteraction detection terms. As far as I'm concerned, the optimal arrangement would be to get rid of MI:0230 with MI:0228 altogether, place all the child terms, together with MI:0232 (transcriptional complementation assay) branch directly within MI:0090 (protein complementation assay), and, finally, merge MI:0229 and MI:0809 into one generic term.
Reported by: lukasz99